Item 8.01 Other Events.
On January 14, 2021, aTyr Pharma, Inc. (the "Company") announced that its
partner Kyorin Pharmaceutical Co., Ltd., a wholly owned subsidiary of Kyorin
Holdings, Inc., has completed the last subject visit in its Phase 1 clinical
trial of aTyr's lead therapeutic candidate ATYR1923 (known as KRP-R120 in
Japan). This achievement has triggered a $2.0 million milestone payment to the
Company.
A press release announcing the completion of subject visits for the Phase 1
trial of ATYR1923 in Japan is attached as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of aTyr Pharma, Inc. dated January 14, 2021
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses